Illumina Inc. (ILMN): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Illumina ( ILMN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.7%. By the end of trading, Illumina rose $1.17 (2.3%) to $51.69 on light volume. Throughout the day, 1.1 million shares of Illumina exchanged hands as compared to its average daily volume of 1.8 million shares. The stock ranged in a price between $50.40-$52 after having opened the day at $50.55 as compared to the previous trading day's close of $50.52. Other companies within the Health Care sector that increased today were: CombiMatrix Corporation ( CBMX), up 22%, Sequenom ( SQNM), up 15.2%, Vivus ( VVUS), up 13.3%, and BG Medicine ( BGMD), up 11.5%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $6.18 billion and is part of the drugs industry. The company has a P/E ratio of 71.5, above the S&P 500 P/E ratio of 17.7. Shares are up 65.7% year to date as of the close of trading on Tuesday. Currently there are nine analysts that rate Illumina a buy, one analyst rates it a sell, and six rate it a hold.

TheStreet Ratings rates Illumina as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, premium valuation and weak operating cash flow.

On the negative front, Dynatronics Corporation ( DYNT), down 11.1%, Arrhythmia Research Technology ( HRT), down 9.1%, Supernus Pharmaceuticals ( SUPN), down 8.9%, and Heartware International ( HTWR), down 8.8%, were all laggards within the health care sector with St Jude Medical ( STJ) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

IPOs That Should Be on Your Radar

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Trader's Daily Notebook: Anemic Trading Would Be an Improvement